234.20 0.00 (0.00%)
After hours: 4:25PM EDT
|Bid||221.00 x 800|
|Ask||272.00 x 800|
|Day's Range||233.12 - 239.70|
|52 Week Range||15.53 - 325.98|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||320.00|
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after the Trump administration released details on the latest round of China tariffs, to which China has responded in kind. In other news, the June Empire State Manufacturing Survey beat Wall Street expectations on nearly every front.
On August 6, Intercept Pharmaceuticals’ (ICPT) stock price grew ~17.94% to $114.71—compared to the previous day’s closing price of $97.26. On August 6, Intercept Pharmaceuticals’ stock price closed at $114.71, which represents ~125% growth from its 52-week low of $51.05 on February 9.
CONSHOHOCKEN, Pa., Aug. 07, 2018-- Madrigal Pharmaceuticals, Inc. today announced its second quarter 2018 financial results and described recent clinical and corporate accomplishments including:. Positive ...
Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) is positioned to dominate a “ blockbuster market,” according to Goldman Sachs. But while the bank believes in the biotech’s longer-term prospects, it sees no ...
While the company doesn’t even list its name or display its logo on the entrance of the shared office space it occupies in West Conshohocken, Madrigal Pharmaceuticals is anonymous no longer. The 7-year-old company has experienced a rapid rise in its stock price and market capitalization, which at the start of the week was at $4.4 billion. In the past year, the company’s stock has soared from $15.50 a share to more than $300, hitting a 52-week high of $325.98 last month.
Stock Research Monitor: KTOV, LOXO, and MDGL LONDON, UK / ACCESSWIRE / July 17, 2018/ If you want a free Stock Review on MRTX sign up now at www.wallstequities.com/registration . Today, WallStEquities.com ...
NEW YORK, NY / ACCESSWIRE / July 3, 2018 / U.S. equities closed up on Monday, supported by a rally from the technology sector. However, growing trade concerns continue to weigh on the markets. The Dow ...
This article is a part of InvestorPlace’s Best ETFs for 2018 contest. Todd Shriber’s pick for the contest is the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO). Albeit modestly, healthcare is one of the four sectors higher YTD, and biotechnology stocks are a big reason.
Evercore ISI's Josh Schimmer on June 19 upgraded bluebird from In-line to Outperform with a price target lifted from $175 to $230. Bluebird's recent updates related to its LentiGlobin investigational gene therapy in patients with sickle cell disease and the separate myeloma CAR-T therapy bb2121 with its partner Celgene Corporation (NASDAQ: CELG) represent an "important positive inflection" for the company, Schimmer said in the upgrade note.
Madrigal Pharmaceuticals Inc., with just nine employees and a market value of about $4.3 billion, is exploring a sale after receiving takeover interest from other drugmakers eyeing treatments for a liver disease linked to obesity, people familiar with the matter said. The deliberations are at an early stage and Madrigal may opt to continue operations on its own, they said. Representatives for Madrigal declined to comment, while Centerview didn’t immediately respond to calls.
CONSHOHOCKEN, Pa., June 06, 2018-- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the ...
CONSHOHOCKEN, Pa., June 05, 2018-- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the ...
LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want access to our free research report on Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MDGL as the Company's latest news hit the wire. On May 31, 2018, the Company announced positive top-line, 36-week results from a Phase-2 clinical trial assessing MGL-3196, a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) β-selective agonist, in patients with biopsy-proven non-alcoholic steatohepatitis (NASH). Active-Investors.com is currently working on the research report for Pulmatrix, Inc. (NASDAQ: PULM), which also belongs to the Healthcare sector as the Company Madrigal Pharma.
The mid-stage trial results sent the shares of many rivals in the NASH space downBloomberg NewsDMAMBMCMDMEMGZBZBRZDZDRZFZGZQZRZSZTZUMadrigal Pharmaceuticals Inc. shares soared as much as 145% in extremely heavy Thursday trade after the company released positive results for a phase 2 clinical trial for a type of liver disease called non-alcoholic steatohepatitis, or NASH.